ROCO
4111
Market cap54mUSD
Oct 08, Last price
29.00TWD
1D
0.52%
1Q
-4.45%
Jan 2017
30.63%
Name
Chi Sheng Pharma & Biotech Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chi Sheng Pharma & Biotech Co., Ltd. is a Taiwan-based company actively engaged in the development, production, distribution, and international trade of a diverse range of products. Operating across both domestic and global markets, the company specializes in pharmaceuticals, medical products, cosmetics, health foods, and medical equipment. Its extensive product portfolio covers numerous therapeutic categories, including antibiotics, chemotherapeutic agents, plasma substitutes, amino acid preparations, water nutrients, electrolyte solutions, and vitamins. Additionally, the company provides hepatotropic agents, hormones, adrenal cortical steroids, autonomic nerve agents, antihistamines, antipruritics, antipyretics, analgesics, antitussives, anti-asthmatics, gastro-intestinal preparations, and local anesthetic solutions. Further extending its offerings, Chi Sheng Pharma & Biotech supplies hemodialysis concentrates, peritoneal dialysis solutions, and various other specialized medical items. Beyond medicinal products, the company provides medical devices, fat emulsion products, anesthetics, hemostatic solutions, food products, functional beverages, skincare items, and veterinary medicines. It also offers external solutions such as those for contact lenses, saline, and iodine. The company was founded in 1962 and maintains its headquarters in Hsinchu, Taiwan.
Key people
Dongmao Su
Chairman of the Board, General Manager · since 2003
Wujin Dai
Deputy General Manager-International Business & Management · since 2006
Huizhen Huang
Head of Finance and Accounting, Corporate Governance Officer · since 2023
Yuanqiong Li
Director · since 2024
Rongyao Lin
Director · since 2009
Xiuying Shen Yu
Director
Yaotang Shi
Director · since 2024
Yujun Su
Director · since 2021
Jiajun Su
Director · since 2009
Dongyu Su
Director · since 2003
Mingxun Xie
Director · since 2012
Independent Director · since 2018
Zhenguang Ling
Independent Director
Wenqi Shen
Independent Director
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||